Pallavi R Devchand1. 1. Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard University, Boston, Massachusetts 02115, USA. pdevchand@rics.bwh.harvard.edu
Abstract
PURPOSE OF REVIEW: To chart recent progress on molecular mechanisms of rosiglitazone and pioglitazone in the cardiovascular system. RECENT FINDINGS: Several classes of oral antidiabetic drugs are available to treat type 2 diabetes, but glitazones offer the unique promise of insulin-sensitizing ability coupled with potential to reverse cardiovascular abnormalities associated with insulin resistance. Currently the two drugs used are rosiglitazone and pioglitazone, marketed as Avandia and Actos. Recent results of different metaanalyses were inconclusive as to whether rosiglitazone caused real adverse effects of myocardial ischemia. Thus, the US Food and Drugs Administration placed a black box warning on Avandia to signal potential of myocardial infarction and heart-related deaths, as a precautionary measure until analyses of all available data provide clarity. Also unresolved is the extent to which the two compounds share modes of action. SUMMARY: Type II diabetes affects more than 160 million people, approximately 5% of the world's population (http://www.who.org). Recently, questions have been raised about the cardiovascular safety of glitazone antidiabetic drugs. Clearly, there is an urgency to define molecular mechanisms of rosiglitazone and pioglitazone and understand how these drugs may impact patients.
PURPOSE OF REVIEW: To chart recent progress on molecular mechanisms of rosiglitazone and pioglitazone in the cardiovascular system. RECENT FINDINGS: Several classes of oral antidiabetic drugs are available to treat type 2 diabetes, but glitazones offer the unique promise of insulin-sensitizing ability coupled with potential to reverse cardiovascular abnormalities associated with insulin resistance. Currently the two drugs used are rosiglitazone and pioglitazone, marketed as Avandia and Actos. Recent results of different metaanalyses were inconclusive as to whether rosiglitazone caused real adverse effects of myocardial ischemia. Thus, the US Food and Drugs Administration placed a black box warning on Avandia to signal potential of myocardial infarction and heart-related deaths, as a precautionary measure until analyses of all available data provide clarity. Also unresolved is the extent to which the two compounds share modes of action. SUMMARY:Type II diabetes affects more than 160 million people, approximately 5% of the world's population (http://www.who.org). Recently, questions have been raised about the cardiovascular safety of glitazone antidiabetic drugs. Clearly, there is an urgency to define molecular mechanisms of rosiglitazone and pioglitazone and understand how these drugs may impact patients.
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef Journal: J Clin Endocrinol Metab Date: 2012-09 Impact factor: 5.958
Authors: Jeff S Volek; Stephen D Phinney; Cassandra E Forsythe; Erin E Quann; Richard J Wood; Michael J Puglisi; William J Kraemer; Doug M Bibus; Maria Luz Fernandez; Richard D Feinman Journal: Lipids Date: 2008-12-12 Impact factor: 1.880
Authors: Pallavi R Devchand; Tianyun Liu; Russ B Altman; Garret A FitzGerald; Eric E Schadt Journal: Front Pharmacol Date: 2018-10-04 Impact factor: 5.810
Authors: Kusuma Kumari G; Praveen Thaggikuppe Krishnamurthy; Ravi Kiran Ammu V V V; Kurawattimath Vishwanath; S T Narenderan; B Babu; Nagappan Krishnaveni Journal: RSC Adv Date: 2021-03-18 Impact factor: 3.361